Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. Holland TL, et al. Among authors: file tm jr. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530858 Free PMC article. Clinical Trial.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F, File TM, Wilcox MH, Torres A, Dryden M, Holland TL, McLeroth P, Shukla R, Corey GR. Huang DB, et al. Among authors: file tm. Clin Infect Dis. 2018 Apr 3;66(8):1222-1229. doi: 10.1093/cid/cix987. Clin Infect Dis. 2018. PMID: 29281036 Free article. Clinical Trial.
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
Noviello S, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM, Dryden M, Balser B, Scaramucci A, Torres A, Huang DB. Noviello S, et al. Among authors: file tm. J Med Microbiol. 2020 Apr;69(4):625-630. doi: 10.1099/jmm.0.001177. J Med Microbiol. 2020. PMID: 32195649 Free article. Clinical Trial.
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR. Huang DB, et al. Among authors: file tm jr. Clin Ther. 2017 Aug;39(8):1706-1718. doi: 10.1016/j.clinthera.2017.07.007. Epub 2017 Jul 27. Clin Ther. 2017. PMID: 28756068 Free article. Clinical Trial.
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M; 185 Gemifloxacin Study Group. Lode H, et al. Among authors: file tm jr. Clin Ther. 2002 Nov;24(11):1915-36. doi: 10.1016/s0149-2918(02)80088-1. Clin Ther. 2002. PMID: 12501883 Clinical Trial.
267 results